About Electromed (NYSEMKT:ELMD)
Electromed, Inc. develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company's products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others. As of June 30, 2016, the SmartVest System is available in two models: SV2100 and SQL. The SmartVest System consists of an inflatable therapy garment, a programmable air pulse generator and a single-hose, which delivers air pulses from the generator to the garment. The SmartVest SQL System is small, quiet and light, and offers generator programmability. The Company markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to healthcare providers, particularly those working in intensive care units. The Company sells its products to the home healthcare market for patients with chronic lung issues, including bronchiectasis, cystic fibrosis and neuromuscular disease.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: NYSEMKT:ELMD
- CUSIP: N/A
- Web: smartvest.com/
- Market Cap: $61.62 million
- Outstanding Shares: 8,260,000
- 50 Day Moving Avg: $7.29
- 200 Day Moving Avg: $5.87
- 52 Week Range: $3.38 - $7.96
Sales & Book Value:
- Trailing P/E Ratio: 28.69
- Foreward P/E Ratio: 32.43
- P/E Growth: 0.00
- Annual Revenue: $25.86 million
- Price / Sales: 2.38
- Book Value: $2.32 per share
- Price / Book: 3.22
- EBITDA: $4.46 million
- Net Margins: 13.01%
- Return on Equity: 20.48%
- Return on Assets: 16.89%
- Average Volume: 37,558 shs.
- Beta: 0.89
- Short Ratio: 2.41
Frequently Asked Questions for Electromed (NYSEMKT:ELMD)
What is Electromed's stock symbol?
Electromed trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ELMD."
How were Electromed's earnings last quarter?
Electromed, Inc. (NYSEMKT:ELMD) posted its quarterly earnings data on Tuesday, September, 5th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. The firm earned $7.27 million during the quarter. Electromed had a return on equity of 20.48% and a net margin of 13.01%. View Electromed's Earnings History.
Who are some of Electromed's key competitors?
Some companies that are related to Electromed include Neovasc (NVCN), IRIDEX Corporation (IRIX), Viveve Medical (VIVE), EDAP TMS S.A. (EDAP), Presbia PLC (LENS), FULGENT GENETIC (FLGT), Biolase (BIOL), Invivo Therapeutics Holdings Corp (NVIV), Digirad Corporation (DRAD), Luna Innovations Incorporated (LUNA), EnteroMedics (ETRM), Advanced Oncotherapy PLC (AVO), Xtant Medical Holdings (XTNT), Dynatronics Corporation (DYNT), Dextera Surgical (DXTR), PhotoMedex (PHMD), Alliance HealthCare Services (AIQ) and BIOLASE (BLTI).
Who are Electromed's key executives?
Electromed's management team includes the folowing people:
- Stephen H. Craney, Independent Chairman of the Board
- Kathleen S. Skarvan, President, Chief Executive Officer
- George H. Winn DDS, Vice Chairman, Independent Director
- Jeremy T. Brock CPA, Chief Financial Officer
- William V. Eckles, Independent Director
- Stan K. Erickson, Independent Director
- Lee A. Jones, Independent Director
How do I buy Electromed stock?
Shares of Electromed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Electromed's stock price today?
MarketBeat Community Rating for Electromed (NYSEMKT ELMD)MarketBeat's community ratings are surveys of what our community members think about Electromed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Electromed stock can currently be purchased for approximately $7.46.
Consensus Ratings for Electromed (NYSEMKT:ELMD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Electromed (NYSEMKT:ELMD)
Analysts' Ratings History for Electromed (NYSEMKT:ELMD)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Electromed (NYSEMKT:ELMD)Earnings History by Quarter for Electromed (NYSEMKT ELMD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/5/2017||Q4 2017||$0.06||$0.11||$7.27 million||View||Listen|
|5/15/2017||Q3 2017||$0.06||$0.08||$6.67 million||View||N/A|
|2/7/2017||Q217||$0.03||$0.05||$6.21 million||$6.40 million||View||Listen|
|11/8/2016||Q117||$0.03||$0.02||$5.90 million||$5.50 million||View||Listen|
|9/6/2016||Q416||$0.05||$0.04||$6.03 million||$5.69 million||View||N/A|
|5/10/2016||Q3||$0.07||$0.06||$5.70 million||$6.04 million||View||N/A|
|11/10/2015||Q116||$0.04||$4.77 million||$5.00 million||View||N/A|
|9/15/2015||Q415||$0.02||$0.03||$4.67 million||$5.20 million||View||N/A|
|2/10/2015||Q115||$0.05||$4.00 million||$4.90 million||View||N/A|
|11/12/2014||Q1 2015||($0.01)||$0.05||$3.91 million||$4.77 million||View||N/A|
|9/23/2014||Q414||$0.04||$4.00 million||$4.61 million||View||N/A|
|5/13/2014||Q314||($0.12)||$3.80 million||$0.96 million||View||N/A|
|2/11/2014||Q214||($0.03)||($0.03)||$3.54 million||$3.50 million||View||N/A|
|9/25/2013||Q413||($0.05)||($0.05)||$3.55 million||$4.02 million||View||N/A|
|2/13/2013||Q213||($0.05)||$4.80 million||$3.85 million||View||N/A|
Earnings Estimates for Electromed (NYSEMKT:ELMD)
Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $0.23 EPS
Dividend History for Electromed (NYSEMKT:ELMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Electromed (NYSEMKT:ELMD)Insider Trades by Quarter for Electromed (NYSEMKT:ELMD)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/3/2017||Red Oak Partners, Llc||Major Shareholder||Sell||34,858||$7.50||$261,435.00|| |
|10/2/2017||Red Oak Partners, Llc||Major Shareholder||Sell||4,600||$7.51||$34,546.00|| |
|9/22/2017||Red Oak Partners, Llc||Major Shareholder||Sell||7,455||$7.40||$55,167.00|| |
|9/21/2017||Red Oak Partners, Llc||Major Shareholder||Sell||262,475||$7.52||$1,973,812.00|| |
|9/20/2017||Red Oak Partners, Llc||Major Shareholder||Sell||184,336||$7.53||$1,388,050.08|| |
|3/13/2017||Stephen H Craney||Director||Buy||10,000||$4.64||$46,400.00|| |
|12/5/2016||Stan K Erickson||Director||Buy||1,500||$3.76||$5,640.00|| |
|12/1/2016||Stephen H Craney||Director||Buy||5,000||$3.75||$18,750.00|| |
|11/10/2016||William Eckles||Director||Buy||20,000||$3.61||$72,200.00|| |
|5/17/2016||Red Oak Partners, Llc||Major Shareholder||Buy||8,900||$3.81||$33,909.00|| |
|5/16/2016||Red Oak Partners, Llc||Major Shareholder||Buy||67,531||$3.74||$252,565.94|| |
|5/12/2016||Red Oak Partners, Llc||Major Shareholder||Buy||78,082||$3.84||$299,834.88|| |
|11/16/2015||William Eckles||Director||Buy||60,000||$2.11||$126,600.00|| |
|3/16/2015||Stephen H Craney||Director||Buy||9,900||$2.35||$23,265.00|| |
|12/9/2014||William Eckles||Director||Buy||10,000||$2.46||$24,600.00|| |
|2/25/2013||Stephen H Craney||Director||Buy||50,000||$1.40||$70,000.00|| |
|2/21/2013||Kathleen Skarvan||CEO||Buy||6,050||$1.35||$8,167.50|| |
|2/15/2013||Kathleen Skarvan||CEO||Buy||2,900||$1.35||$3,915.00|| |
|12/14/2012||Kathleen Skarvan||CEO||Buy||8,000||$1.47||$11,760.00|| |
|12/14/2012||Stephen H Craney||Director||Buy||20,000||$1.49||$29,800.00|| |
|12/11/2012||Kathleen Skarvan||CEO||Buy||7,000||$1.41||$9,870.00|| |
|11/15/2012||William Eckles||Director||Buy||9,311||$1.56||$14,525.16|| |
Headline Trends for Electromed (NYSEMKT:ELMD)
Latest Headlines for Electromed (NYSEMKT:ELMD)
Loading headlines, please wait.
Electromed (ELMD) Chart for Sunday, October, 22, 2017